Dashboard

Vertex Pharmaceuticals, Inc. (VRTX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

CEO

Reshma Kewalramani

Employees

3,000

Industry

Respiratory System Biopharmaceuticals

Sector

Healthcare

Headquarters

Boston

Exchange

NASDAQ

Summary Stats

Market Cap

80.5B

Revenue

8.93B

Net Income

3.32B

EPS

$12.82

Price-to-Earnings

24.43

Price-to-Book

5.79

Debt-to-Equity

0.31

News

Analyst Ratings

Price targets projected by 24 analysts

High

$356.00

Average

$287.75

Low

$220.00

Ratings calculated by 28 analysts

Buy

22

Hold

6

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q4 2022

Last Earnings

Above by $0.25

Actual

$3.76 +7.1%

Consensus

3.51

Report Date

Year Ago

3.37

Year Ago Change %

Up 11%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites